|
Soler-Espejo E., Marín F., López-Gálvez R., Ramos-Bratos M.P., Sánchez-Villalobos M., Esteve-Pastor M.A., Lip G.Y.H., Rivera-Caravaca J.M., Roldán V. The Neutrophil-to-Lymphocyte Ratio Is an Independent Inflammatory Biomarker for Adverse Events in Patients With Atrial Fibrillation: Insights From the Murcia AF Project II (MAFP-II) Cohort Study. Clinical Cardiology. February 2025. 48. 10.1002/clc.70102
AÑO: 2025; IF: 2.3
|
39985306
|
Soler-Espejo E, Rivera-Caravaca JM. Navigating the bleeding risk dilemma in patients with atrial fibrillation on therapy with direct-acting oral anticoagulants: Comparing the HAS-BLED vs. DOAC Score. Eur J Intern Med. 2024 Oct;128:36-39. doi: 10.1016/j.ejim.2024.07.031. Epub 2024 Jul 27. No abstract available. PubMed PMID: 39068124.
AÑO: 2024; IF: 6.1
|
|
Soler-Espejo E, Marin F, Roldan V, Rivera-Caravaca JM. What is the impact of dynamic score reassessment for stroke and bleeding risk outcome prediction in atrial fibrillation patients? Expert Rev Cardiovasc Ther. 2025 Apr;23(4):107-112. doi: 10.1080/14779072.2025.2489725. Epub 2025 Apr 10. PubMed PMID: 40202395.
AÑO: 2025; IF: 2.1
|
|
Rivera-Caravaca JM, Menichelli D, Pastori D, Soler-Espejo E, Esteve-Pastor MA, Vivas D, Roldan I, Anguita M, Luis Ferreiro J, Roldan V, Marin F; Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. Quality of anticoagulation with vitamin K antagonists in Spain: A systematic review with meta-analysis of national registries. Med Clin (Barc). 2025 Jun 3;165(3):107031. doi: 10.1016/j.medcli.2025.107031. Online ahead of print. English, Spanish. PubMed PMID: 40466270.
AÑO: 2025; IF: 2.1
|
|
Rivera-Caravaca JM, Soler-Espejo E, Ramos-Bratos MP, Lopez-Galvez R, Gonzalez-Lozano E, Lip GYH, Marin F, Roldan V. The triglyceride-glucose index, a marker of insulin resistance, as a predictor of thrombotic risk in atrial fibrillation. Cardiovasc Diabetol. 2025 Jul 10;24(1):281. doi: 10.1186/s12933-025-02809-2. PubMed PMID: 40640827; PubMed Central PMCID: PMC12247220.
AÑO: 2025; IF: 10.6
|